Michael Grey
Scientific Advisory Board
Mike has 30 years of experience in the biopharmaceutical industry and is currently President and CEO of SGX Pharmaceuticals (formerly Structural GenomiX). Prior to joining SGX in 2001, Mike served as President and CEO of Trega Biosciences until its acquisition by Lion Bioscience. He also served as President of BioChem Therapeutics, a subsidiary of BioChem Pharma, from 1994 to 1998. From 1974 to 1993, Mike served in various roles with Glaxo Holdings plc and Glaxo Inc., including positions as Vice President, Corporate Development, and Director, International Licensing. Mike currently serves on the board of directors of Achillion Pharmaceuticals and IDM Pharma (formerly known as Epimmune).